arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

bioAffinity Technologies, Inc.

BIAF
$0.51 ▼ -0.02 (-2.91%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
6 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

bioAffinity Technologies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -34.2%
Op. Margin -171.6%
ROIC -145.7%
FCF / Share $-5.46
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.16M
↓ -34.2%
Net Income Profit after all expenses
$-14.91M
↓ -64.9%
Operating Margin Operating profit as % of sales
-171.6%
↓ -79.4% 1th
FCF / Share Free cash flow per share
$-5.46
↑ +70.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
2
Financial Health
51
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters